Elite Pharmaceuticals Inc. logo

Elite Pharmaceuticals Inc. (ELTP)

Market Closed
5 Dec, 20:00
OTCQB OTCQB
$
0. 52
0
0%
$
708.48M Market Cap
6.76 P/E Ratio
0% Div Yield
1,223,700 Volume
0 Eps
$ 0.52
Previous Close
Day Range
0.51 0.52
Year Range
0.27 0.82
Want to track ELTP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ELTP closed Friday higher at $0.52, an increase of 0% from Thursday's close, completing a monthly decrease of -3.7% or $0.02. Over the past 12 months, ELTP stock lost -5.45%.
ELTP is not paying dividends to its shareholders.
The last earnings report, released on Nov 13, 2025, exceeded the consensus estimates by 0.01%. On average, the company has surpassed earnings expectations by 0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTCQB (USD).

ELTP Chart

ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance

ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance

Elite Pharmaceuticals delivers record second-quarter fiscal 2026 earnings as lisdexamfetamine sales surged, though margins faced competitive pressure.

Zacks | 2 weeks ago
Elite Pharmaceuticals, Inc. (ELTP) Q2 2026 Earnings Call Transcript

Elite Pharmaceuticals, Inc. (ELTP) Q2 2026 Earnings Call Transcript

Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Q2 2026 Earnings Call November 17, 2025 11:30 AM EST Company Participants Nasrat Hakim - Chairman, CEO & President Carter Ward - CFO, Secretary & Treasurer Presentation Operator Good morning, ladies and gentlemen, and welcome to the Elite Pharmaceuticals Second Quarter of Fiscal Year 2026 Conference Call. [Operator Instructions] Before management begins speaking, the conference has the following statement.

Seekingalpha | 2 weeks ago
ELTP Stock Gains Following Q1 Earnings Showing Strong Revenue Growth

ELTP Stock Gains Following Q1 Earnings Showing Strong Revenue Growth

Elite Pharmaceuticals reports strong first-quarter fiscal 2026 results with rising direct sales, higher-margin products and expanding gross profit.

Zacks | 3 months ago

Elite Pharmaceuticals Inc. (ELTP) FAQ

What is the stock price today?

The current price is $0.52.

On which exchange is it traded?

Elite Pharmaceuticals Inc. is listed on OTCQB.

What is its stock symbol?

The ticker symbol is ELTP.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 708.48M.

Has Elite Pharmaceuticals Inc. ever had a stock split?

No, there has never been a stock split.

Elite Pharmaceuticals Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Mr. Nasrat Hakim CEO
OTCQB Exchange
US28659T2006 ISIN
US Country
53 Employees
- Last Dividend
- Last Split
23 Jul 1998 IPO Date

Overview

Elite Pharmaceuticals, Inc. is a distinguished specialty pharmaceutical company focused on the development, manufacturing, and marketing of oral, controlled-release, and generic pharmaceuticals. The company is actively involved in two major pharmaceutical segments: Abbreviated New Drug Applications (ANDAs) for Generic Pharmaceuticals and New Drug Applications (NDAs) for Branded Pharmaceuticals. Since its inception in 1997, Elite Pharmaceuticals has been committed to providing advanced therapeutic solutions and has established itself as a player in the pharmaceutical industry with a robust product portfolio and a pipeline of developed drugs. Headquartered in Northvale, New Jersey, Elite Pharmaceuticals strives to address the needs of patients across various therapeutic areas with its innovative drug delivery technologies and manufacturing capabilities.

Products and Services

Elite Pharmaceuticals offers a comprehensive range of generic and branded pharmaceutical products targeting a variety of therapeutic areas. The company leverages its expertise in oral dose pharmaceuticals to serve the bariatric, pain management, cardiovascular, central nervous system, muscle relaxant, antipsychotic, and antibiotic sectors, among others. Below is an outline of their key products and services:

  • Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules - Marketed under the Adipex-P brand, these products are designed for bariatric use, aiding in weight loss.
  • Phendimetrazine Tartrate 35mg tablets - Available under the Bontril brand, this medication is also intended for bariatric use, specifically for weight loss.
  • Naltrexone HCl 50mg tablets - Branded as Revia, these tablets are prescribed for pain management.
  • Isradipine 2.5mg and 5mg capsules - Aimed at treating cardiovascular diseases, these capsules help manage blood pressure.
  • Trimipramine Maleate Immediate Release capsules - Sold under the Surmontil brand, these capsules are used as antidepressants.
  • Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets - Known under the Adderall brand, and its extended-release variant under the Adderall XR brand, these products target central nervous system diseases, specifically for managing ADHD symptoms.
  • Dantrolene Sodium capsules - Marketed as Dantrium, these capsules function as muscle relaxants.
  • SequestOX - An innovative formulation combining immediate-release Oxycodone with Naltrexone for pain management.
  • Loxapine Succinate capsules - Offered under the Loxapine brand, these capsules are utilized for their antipsychotic properties.
  • Acetaminophen and Codeine Phosphate - A combination used for the management of mild to moderate pain.
  • Antibiotic Products - Elite Pharmaceuticals also develops antibiotic products aiming to combat various infections.

In addition to its comprehensive portfolio, Elite Pharmaceuticals actively engages in the contract manufacturing of controlled-release products for third-party clients, covering pain, allergy, bariatric, attention deficit, and infection therapies. Furthermore, the company is at the forefront of developing abuse-deterrent opioid products, reflecting its commitment to addressing the ongoing opioid crisis while meeting medical needs.

Contact Information

Address: 165 Ludlow Avenue, Northvale, NJ, United States, 07647
Phone: 201 750 2646